ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

M. Ohira1, Y. Imaoka2, K. Sato3, K. Imaoka1, N. Tanimine1, H. Tahara1, K. Ide1, T. Kobayashi1, Y. Tanaka1, A. G. Tzakis4, S. Nishida5, H. Ohdan1

1Hiroshima University, Hiroshima, Japan, 2Hiroshima Uni., Hiroshima, Japan, 3Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan, 4Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, 5Univ of Miami School of Medicine, Valhalla, NY

Meeting: 2022 American Transplant Congress

Abstract number: 33

Keywords: Hepatocellular carcinoma, Liver transplantation, Natural killer cells, Tumor recurrence

Topic: Clinical Science » Liver » 56 - Liver: Hepatocellular Carcinoma and Other Malignancies

Session Information

Session Name: Hepatocellular Carcinoma and Other Malignancies

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 5, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 3:40pm-3:50pm

Location: Hynes Room 312

*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after LT reduce the proportion of adaptive components of cellular immunity while maintaining innate components. Natural killer (NK) cells play a central role in innate immunity against neoplastic cells; therefore, their augmentation is a promising immunotherapeutic approach against HCC recurrence after LT.

*Methods: We propose that adoptive transfer of IL-2-stimulated TRAIL+ NK cells extracted from donor liver graft perfusate can mount an anti-tumor response without causing toxicity to intact recipient tissues.

*Results: In the 98 patients who met the Japan criteria preoperatively, the postoperative pathologically exceeding the Milan criteria (n=41) had a significantly poorer recurrence-free survival rate than those within the Milan criteria (n=57) (p=0.022). However, among the cases outside the Milan criteria, 17 cases treated with NK cell therapy had a significantly better recurrence-free survival rate. After infusion of NK cells, the NK cytotoxicity and the proportion of TRAIL+ NK cells in the peripheral blood of patients increased significantly (p<0.05). The inoculated donor NK cells could be confirmed up to 1 month through the analysis of peripheral blood chimerism. We also applied the proposed approach to the deceased donor LT (DDLT) recipients in collaboration with the US since 2009. This phase I study included 17 subjects with a median follow-up of 96 months. No study-related adverse events were noted in either of the studies. Regarding overall survival, the high-dose group had significantly better survival than the low-dose group (p = 0.0064). In the series of DDLT with HCC, among the 17 patients who met MC on preoperative imaging, 9 patients (53%) had HCC exceeding MC on postoperative pathology. None of the patients have shown any symptom of HCC recurrence. Interestingly, the number of HLA mismatch between donor and recipient was associated with tumor recurrence after NK cell therapy.

*Conclusions: In conclusions, the administration of IL-2-stimulated NK cells derived from both living and deceased donor liver allografts was safely applied and is, therefore, a potential novel adjuvant immune treatment after LT in HCC patients.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ohira M, Imaoka Y, Sato K, Imaoka K, Tanimine N, Tahara H, Ide K, Kobayashi T, Tanaka Y, Tzakis AG, Nishida S, Ohdan H. Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-efficacy-of-adjuvant-immunotherapy-for-liver-transplant-recipients-with-exceeding-japan-criteria-of-hepatocellular-carcinoma-using-donor-liver-derived-natural-killer-cells/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences